BigHat Biosciences Announces First Patient Dosed in Phase 1 Trial Evaluating BHB810, a Novel CDH17-Directed Antibody-Drug Conjugate, for the Treatment of Gastric Cancer and other Advanced Gastrointestinal Tumors - BioSpace
BigHat Biosciences Announces First Patient Dosed in Phase 1 Trial Evaluating BHB810, a Novel CDH17-Directed Antibody-Drug Conjugate, for the Treatment of Gastric Cancer and other Advanced Gastrointestinal Tumors BioSpace